Vol. 6, Issue 1, Part A (2024)

Background: Rosacea is a chronic but treatable skin condition that primarily affects the central face, and is often characterized by flare-ups and remissions
Aim: The aim of present study was to evaluate the efficacy of PRP as a new therapeutic intervention in treatment of patients with rosacea.
Patients and Methods: This prospective cohort study was conducted on among 45 patients in Kirkuk city, conducted from August 15, 2023, to March 2024. Patients meeting inclusion criteria, including absence of previous treatment within 3 months and voluntary participation, underwent thorough clinical examinations, including the assessment of rosacea lesions using the Rosacea Grading Scale (RGS). PRP is prepared using the double-spin method and administered intradermally and subcutaneously into rosacea sites over six sessions at 2-week intervals. Efficacy was evaluated using RGS scores, Global Aesthetic Improvement Scale (GAIS), and patient satisfaction, with adverse events monitored. Demographic characteristics were similar between treatment groups. Results indicated a significant reduction in RGS scores post-treatment (p < 0.001), with sustained improvement observed at the 3-month follow-up. GAIS scores reflected notable improvement, and patient satisfaction increased over time. Adverse events are minimal.
Results: Following PRP therapy, there was a substantial improvement in RGS scores, indicating notable alleviation of symptoms. This improvement was sustained at the 3-month follow-up, underscoring the enduring efficacy of PRP treatment in managing rosacea symptoms. The statistically significant p-value of 0.001 further supports the effectiveness of PRP therapy in reducing rosacea severity. Similarly, the Global Aesthetic Improvement Scale (GAIS) scores demonstrate the effectiveness of PRP treatment, with none of the patients reporting no improvement. Instead, a majority of patients experienced varying degrees of enhancement, ranging from mild to excellent improvement. After 3 months of PRP treatment and follow-up, the GAIS scores indicate significant and substantial improvement among rosacea patients, with the majority experiencing marked or excellent improvement. Furthermore, the data reveal a consistent increase in patient satisfaction with PRP treatment over time. The proportion of patients reporting being "Very satisfied" with the treatment steadily rises across different time points post-treatment, reaching a high of 97.78% at 90 days. This trend reflects both the initial effectiveness of PRP treatment and its enduring positive impact on patient experience. Overall, these findings highlight the sustained and substantial efficacy of PRP treatment in managing rosacea symptoms, as reflected by improvements in RGS and GAIS scores, as well as high levels of patient satisfaction.